MABp1

Drug Profile

MABp1

Alternative Names: CA-18C3; CV-18C3; MAB-p1; RA-18C3; T2-18C3; Xilonix

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator XBiotech
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Interleukin 1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Colorectal cancer; Vascular restenosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Colorectal cancer
  • Phase III Cachexia
  • Phase II Acne vulgaris; Non-small cell lung cancer; Plaque psoriasis; Pyoderma; Type 2 diabetes mellitus; Vascular restenosis
  • Phase I Haematological malignancies

Most Recent Events

  • 22 Feb 2017 The EMA's Committee for Medicinal Products for Human Use extends the timeline for a response to the Day 180 List of Outstanding Issues by 30 days
  • 21 Feb 2017 Independent Data Monitoring Committee (IDMC) recommends continuation of the phase III XCITE trial for Colorectal cancer in USA
  • 15 Feb 2017 XBiotech initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT03047317)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top